Bipolar androgen therapy in the treatment of prostate cancer.
Authors: Denmeade SR PMID: 30067610 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A closer look at blinatumomab.
Authors: Mattison RJ Abstract On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in first or second complete remission (CR) and have minimal residual disease (MRD). Blinatumomab was first approved for use in adult patients (in December 2014) and later in pediatric patients (in September 2016) with relapsed or refractory Philadelphia chromosome (Ph)-negative B-cell precursor ALL; the approval was expanded in July 2017 to include patients with Ph-positive disease....
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cellular immunotherapy for non-Hodgkin lymphoma.
Authors: Bollard C PMID: 30067612 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium.
Authors: Figlin RA PMID: 30067613 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of newly diagnosed or recurrent ovarian cancer.
Authors: Matulonis UA Abstract The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available. Surgery and combination treatment with carboplatin and paclitaxel are the standard of care for patients with newly diagnosed disease, although the use of neoadjuvant chemotherapy is increasing. Clinical strategies have also evolved along with the understanding that ovarian cancer is not one disease but rather comprises several with different histologic and underlying genetic characteristics. The most common histologic type is ...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Contemporary management of advanced renal cell carcinoma.
Authors: Khanna A, Crane A, Yerram N, Sun D, Ericson K, Lundy SD, Abouassaly R Abstract Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease at presentation. Historically, survival outcomes for patients with advanced disease have been poor. In recent years, several novel targeted agents have emerged for the management of advanced renal cell carcinoma that have changed treatment paradigms. At the same time, surgical therapy continues to have a critical role in the management of selected patients. Recent medical a...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent insights into large granular lymphocytic leukemia.
Authors: Nastoupil LJ PMID: 30067616 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New and experimental agents for sickle cell disease.
Authors: Ataga KI PMID: 30067617 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent and ongoing clinical trials in glioblastoma.
Authors: Lombardi G PMID: 30067618 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Authors: Gandhi L PMID: 30067619 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat breast cancer with positive lymph nodes.
Authors: Chagpar AB PMID: 30067620 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Authors: Sulai NH, Tan AR Abstract The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA. The use of PARP inhibitors is a rational therapeutic approach to selectively killing a subset of cancer cells with deficiencies in DNA repair pathways. PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib, niraparib, and rucaparib. The antitumor activity of PARP inhibitors as single agents has been demonstrated in BRCA-associated metastatic breast cancer. In 2018, olaparib became th...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bromodomain inhibitors: what does the future hold?
Authors: Bhattacharya S, Piya S, Borthakur G Abstract Cancer cells are addicted to mutations that cause gain of function in oncogenes and loss of function in tumor suppressors, so that these cells are reliant on aberrant signaling pathways and transcription. Protein-protein and DNA-protein interactions that cause chromatin remodeling are another source of the deregulation of critical signaling and transcriptional regulators, altering epigenetic signatures and creating additional vulnerabilities. Owing to mutations in multiple epigenetic regulators in hematologic malignancies, cancer cells are highly addicted to alt...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Authors: Roboz GJ PMID: 29851927 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Authors: Domchek SM PMID: 29851928 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How should BRAF V600E-mutated colorectal cancer be treated?
Authors: Kopetz S PMID: 29851929 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat chemorefractory metastatic colorectal cancer.
Authors: Chu E PMID: 29851930 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
Authors: Postow MA PMID: 29851931 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Managing adverse effects of immunotherapy.
Authors: Gerson JN, Ramamurthy C, Borghaei H Abstract Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated wit...
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Authors: Lulla PD, Hill LC, Ramos CA, Heslop HE Abstract Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphoma. A major contributor to the success of immunotherapy has been the advent of genetic engineering technologies that introduce a chimeric antigen receptor (CAR) into T cells to focus their killing a...
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in acute myeloid leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition.
Authors: PMID: 29851935 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in acute myeloid leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary.
Authors: DiNardo C PMID: 29851936 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of relapsed/refractory follicular lymphoma.
Authors: Martin P PMID: 29851937 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cytomegalovirus from the 2018 BMT Tandem Meetings.
Authors: PMID: 29851938 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cytomegalovirus from the 2018 BMT Tandem Meetings: commentary.
Authors: Dadwal SS PMID: 29851939 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in colorectal cancer.
Authors: Le DT PMID: 29741500 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Authors: Long G PMID: 29741501 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the management of primary mediastinal large B-cell lymphoma.
Authors: Advani RH PMID: 29741502 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A closer look at copanlisib.
Authors: Dreyling M PMID: 29741503 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Research in drug development for advanced prostate cancer.
Authors: Eisenberger M PMID: 29741504 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Checkpoint inhibition in lymphoma.
Authors: Shah GL, Moskowitz CH Abstract Checkpoint inhibition improves surveillance by the immune system and therefore outcomes in some lymphoma subtypes. In this review, we examine the available evidence regarding checkpoint inhibition in lymphoma by line of therapy. Although most published studies are in the setting of relapsed/refractory disease, several ongoing trials are looking at therapy in the upfront and second-line settings. Nivolumab and pembrolizumab have been approved for patients with relapsed or refractory Hodgkin lymphoma, whereas other programmed death 1 and programmed death ligand 1 monoclonal ant...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.
Authors: Brunner AM, Steensma DP Abstract It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include th...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Authors: PMID: 29741507 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How to manage patients with moderate-risk germline mutations.
Authors: Tung NM PMID: 29741508 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The development of endoxifen for breast cancer.
Authors: Goetz MP PMID: 29741509 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How we treat brain metastases in metastatic renal cell carcinoma.
Authors: Ramalingam S, George DJ, Harrison MR PMID: 29741510 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
Authors: Rini BI PMID: 29741511 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
Authors: Porter DL PMID: 29741512 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Myelofibrosis: clinicopathologic features, prognosis, and management.
Authors: O'Sullivan JM, Harrison CN Abstract Myelofibrosis is one of the BCR-ABL-negative clonal disorders that collectively are known as myeloproliferative neoplasms (MPNs). It is caused by the proliferation of clonal hematopoietic stem cells, which over time leads to characteristic clinical features. The disease presentation is heterogeneous, however, with 30% of patients initially asymptomatic. This variation in clinical phenotype warrants careful risk stratification to guide appropriate management, and prognostic risk scores are continually being refined. Considerable advancements have been made in the understa...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of acute lymphoblastic leukemia in young adults.
Authors: Muffly LS, Reizine N, Stock W Abstract Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that are changing the management paradigm and improving outcomes. The pediatric ALL approach is feasible and effective when administered by medical oncologists. Advanced diagnostics and minimal residual disease measurements aid in prognostication and have resulted in shifting recommendations regarding allogeneic hematopoietic cell transplant in first remission. Blinatumomab, inotuzumab, and chi...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cost-effectiveness in the surgical care of renal cell carcinoma.
Authors: PMID: 29742072 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Are direct acting oral anticoagulants ready for prime-time use in cancer-related thrombosis?
Authors: Streiff MB PMID: 29742073 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging options for combination therapy in multiple myeloma.
Authors: Rossi AC PMID: 29742074 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The timing of molecular imaging in prostate cancer.
Authors: Morris MJ PMID: 29742075 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on hairy cell leukemia.
Authors: Kreitman RJ, Arons E Abstract Hairy cell leukemia (HCL) is a chronic B-cell malignancy with multiple treatment options, including several that are investigational. Patients present with pancytopenia and splenomegaly, owing to the infiltration of leukemic cells expressing CD22, CD25, CD20, CD103, tartrate-resistant acid phosphatase (TRAP), annexin A1 (ANXA1), and the BRAF V600E mutation. A variant lacking CD25, ANXA1, TRAP, and the BRAF V600E mutation, called HCLv, is more aggressive and is classified as a separate disease. A molecularly defined variant expressing unmutated immunoglobulin heavy variable 4-3...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
Authors: Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E Abstract Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for approximately one-fourth of cases of adult ALL. It typically presents with an aggressive clinical course, responds poorly to standard chemotherapy, and carries a high risk for relapse. The landscape of Ph+ ALL therapy has changed favorably since the development of tyrosine kinase inhibitors (TKIs). With the successful incorporation of TKIs into chemotherapy regimens, remissions occur more frequently and patients live longer. Imatinib was the first TK...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
Authors: DiNardo C PMID: 29742078 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current approaches to pregnancy and childbirth in women with von Willebrand disease.
Authors: Johnsen JM PMID: 29742079 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bayesian approaches to evaluating doses of drugs.
Authors: Rosner GL PMID: 29742080 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Looking ahead to new therapies in small cell lung cancer.
Authors: Rudin CM PMID: 29742081 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research